Company Overview
Snapshot
Founded in January 2017 by Bentzi Gruber, Guy Zur, Gerry Waintraub, and Taire Rubin, GWave operates with 1–10 employees. The company has secured $21.1 million across three funding rounds from two investors. In November 2021, GWave was awarded FDA Breakthrough Device Designation for its noninvasive glucose monitoring technology.
Business overview
GWave, operating in the Health Tech & Life Sciences sector, develops a noninvasive glucometer that uses radio frequency waves and proprietary AI algorithms to continuously measure blood glucose levels in real time. Its core product, GWave, is designed to be cost-efficient, compact, and highly accurate, connecting seamlessly to Bluetooth and smartphones for a user-friendly experience. The company serves the healthcare industry, particularly patients and providers, by offering a solution for frequent glucose tracking with automated alarms and secure cloud storage for data, which can be shared with caretakers and medical professionals.
Strategic signal
In August 2023, GWave announced the closing of its Series C funding round, coinciding with the unveiling of new clinical data on its GWave technology. This development signals continued investor confidence and progress in the clinical validation of its non-invasive glucose monitoring solution, reinforcing its potential to disrupt the diabetes care market.
Log in to access full profile ›Company Intelligence Q&A
- What is GWave's primary technology?
- GWave utilizes radio frequency waves combined with proprietary AI algorithms to provide continuous, noninvasive blood glucose monitoring in real time.
- When was GWave awarded FDA Breakthrough Device Designation?
- In November 2021, GWave was awarded FDA Breakthrough Device Designation for its noninvasive glucose monitoring technology, recognizing its potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
- When did GWave close its Series C funding round?
- GWave closed its Series C funding round in August 2023, securing $5 million to advance its non-invasive glucose monitoring technology.
- What was the total funding raised by GWave?
- GWave has raised a total of $21.1 million across three funding rounds. The company secured $5 million in its Series C round in August 2023, and $11.7 million in its Series B round in August 2021, with Columbia Pacific Capital Partners as a lead investor.
- When did GWave raise its Series B funding?
- In August 2021, GWave raised its Series B funding round, with Columbia Pacific Capital Partners as a lead investor.